ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

BOTOX COSMETIC
Aesthetic medicine
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

BOTOX COSMETIC PP

Generic Name and Formulations:
OnabotulinumtoxinA 50 Units, 100 Units; per vial; vacuum-dried pwd for IM inj after reconstitution; contains human albumin; preservative-free.

Company:
Allergan

Therapeutic Use:

Indications for BOTOX COSMETIC:

Temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity and moderate-to-severe lateral canthal lines associated with orbicularis oculi activity.

Adult:

Should be administered and managed by experienced physicians. Max cumulative dose: 360 Units in a 3-month interval. Glabellar: avoid inj near the levator palpebrae superioris or closer than 1cm above central eyebrow. Give 4 Units/0.1mL IM into each of 5 sites (2 in each corrugator muscle and 1 in the procerus muscle); total of 20 Units/0.5mL per treatment session. Lateral canthal: give 4 Units/0.1mL IM into 3 sites per side (6 total inj points) in the lateral orbicularis muscle; total of 24 Units/0.6mL per treatment session. Simultaneous treatment of glabellar and lateral canthal lines: total of 44 Units per session. Repeat treatments more frequently than every 3 months: not evaluated.

Children:

<18yrs: not established.

Contraindications:

Infection at proposed inj site.

Warnings/Precautions:

Not interchangeable with other botulinum toxin products. Risk of distant spread of toxin effect (esp. in children treated for spasticity); see full labeling. Increased risk of serious adverse reactions (including excessive weakness, dysphagia, aspiration pneumonia) with unapproved use. Pre-existing cardiovascular disease, dysphagia, or breathing difficulties. Neuromuscular disorders (eg, ALS, myasthenia gravis, Lambert-Eaton syndrome); monitor closely. Compromised respiratory status; monitor. Presence of inflammation, ptosis, excessive weakness or atrophy at the inj site. Contains human albumin; monitor for possible viral disease and Creutzfeldt-Jakob disease transmission. Elderly. Pregnancy (Cat.C). Nursing mothers.

Interactions:

May be potentiated by aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds). May potentiate anticholinergic effects with concomitant anticholinergic drugs. Concomitant other botulinum toxin products or muscle relaxants may potentiate neuromuscular weakness.

Pharmacological Class:

Neuromuscular blocker.

Adverse Reactions:

Local inj reactions (eg, pain, infection, inflammation, tenderness, erythema), eyelid ptosis, facial pain, muscular weakness, eyelid edema; dysphagia, breathing difficulties, hypersensitivity reactions (discontinue if occur), possible antibody formation.

Generic Availability:

NO

How Supplied:

Single-use vial—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs